Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. / Pedersen-Bjergaard, J.; Specht, L.; Larsen, S.O.; Ersboll, J.; Struck, J.; Hansen, M.M.; Hansen, H.H.; Nissen, N.I.

In: Lancet, Vol. 2, No. 8550, 1987, p. 83-88.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Pedersen-Bjergaard, J, Specht, L, Larsen, SO, Ersboll, J, Struck, J, Hansen, MM, Hansen, HH & Nissen, NI 1987, 'Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy', Lancet, vol. 2, no. 8550, pp. 83-88.

APA

Pedersen-Bjergaard, J., Specht, L., Larsen, S. O., Ersboll, J., Struck, J., Hansen, M. M., Hansen, H. H., & Nissen, N. I. (1987). Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet, 2(8550), 83-88.

Vancouver

Pedersen-Bjergaard J, Specht L, Larsen SO, Ersboll J, Struck J, Hansen MM et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987;2(8550):83-88.

Author

Pedersen-Bjergaard, J. ; Specht, L. ; Larsen, S.O. ; Ersboll, J. ; Struck, J. ; Hansen, M.M. ; Hansen, H.H. ; Nissen, N.I. / Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. In: Lancet. 1987 ; Vol. 2, No. 8550. pp. 83-88.

Bibtex

@article{0dd262104c8f11df928f000ea68e967b,
title = "Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy",
abstract = "391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulative dose of alkylating agents, were related to the risk of t-ANLL. The hazard rate of t-ANLL was roughly proportional to the square of patient age and to the total cumulative dose of alkylating agents. In 320 patients treated with alkylating agents the cumulative risk of t-ANLL increased steadily from 1 year after the start of treatment and reached 13.0% (SE 3.0) at 10 years after which time there were no further cases. Calculated from cessation of therapy with alkylating agents, however, the cumulative risk curve increased steeply during the first 1-2 years then gradually levelled out and no new cases were observed beyond 7 years. With a 15-year follow-up the general risk of solid tumours was not increased.",
author = "J. Pedersen-Bjergaard and L. Specht and S.O. Larsen and J. Ersboll and J. Struck and M.M. Hansen and H.H. Hansen and N.I. Nissen",
note = "DA - 19870812IS - 0140-6736 (Print)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Alkylating Agents)RN - 50-18-0 (Cyclophosphamide)SB - AIMSB - IM",
year = "1987",
language = "English",
volume = "2",
pages = "83--88",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "8550",

}

RIS

TY - JOUR

T1 - Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy

AU - Pedersen-Bjergaard, J.

AU - Specht, L.

AU - Larsen, S.O.

AU - Ersboll, J.

AU - Struck, J.

AU - Hansen, M.M.

AU - Hansen, H.H.

AU - Nissen, N.I.

N1 - DA - 19870812IS - 0140-6736 (Print)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Alkylating Agents)RN - 50-18-0 (Cyclophosphamide)SB - AIMSB - IM

PY - 1987

Y1 - 1987

N2 - 391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulative dose of alkylating agents, were related to the risk of t-ANLL. The hazard rate of t-ANLL was roughly proportional to the square of patient age and to the total cumulative dose of alkylating agents. In 320 patients treated with alkylating agents the cumulative risk of t-ANLL increased steadily from 1 year after the start of treatment and reached 13.0% (SE 3.0) at 10 years after which time there were no further cases. Calculated from cessation of therapy with alkylating agents, however, the cumulative risk curve increased steeply during the first 1-2 years then gradually levelled out and no new cases were observed beyond 7 years. With a 15-year follow-up the general risk of solid tumours was not increased.

AB - 391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulative dose of alkylating agents, were related to the risk of t-ANLL. The hazard rate of t-ANLL was roughly proportional to the square of patient age and to the total cumulative dose of alkylating agents. In 320 patients treated with alkylating agents the cumulative risk of t-ANLL increased steadily from 1 year after the start of treatment and reached 13.0% (SE 3.0) at 10 years after which time there were no further cases. Calculated from cessation of therapy with alkylating agents, however, the cumulative risk curve increased steeply during the first 1-2 years then gradually levelled out and no new cases were observed beyond 7 years. With a 15-year follow-up the general risk of solid tumours was not increased.

M3 - Journal article

VL - 2

SP - 83

EP - 88

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8550

ER -

ID: 19371728